Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.
Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.
复制标题
恶性胸膜间皮瘤治疗的进展：针对 EphA2 的一种新方法。
DOI：
--
复制
发表时间：
2012
影响因子：
5.3
通讯作者：
K. Mohammed
中科院分区：
文献类型：
--
作者：
N. Nasreen;N. Khodayari;K. Mohammed
恶性胸膜间皮瘤是一种侵袭性肿瘤，预后差。MPM从肺表面和胸壁（称为胸膜）的间皮细胞中生长。接触石棉主要与MPM的发展有关。大约80%的肿瘤起源于胸膜，在美国每年有多达3000人被诊断患有MPM。MPM的发病率预计在未来几十年将上升，特别是在发展中国家。虽然人们对使用石棉的危险性的认识有所提高，但由于其耐用性和低成本，在澳大利亚和亚洲仍然普遍使用石棉。这进一步警告并增加了全球MPM患者的死亡率和发病率。传统的治疗策略对这种疾病只有适度的改善。MPM是难以治疗的，因为事实上，暴露于石棉和症状的出现之间的时间是非常延迟的，也由于肿瘤涉及胸膜表面和邻近组织，如胸壁，心包和心包下器官。尽管诊断和治疗方法取得了进展，但MPM的中位生存率在9至17个月之间。双药标准治疗显示出适度的改善，然而，使用新靶点的多模态方法可能有潜力实现生存率的改善。本文对MPM的传统治疗方法进行了综述，并讨论了包括受体EphA2在内的各种分子靶点，EphA2是一种新的靶基因，可作为MPM诊断和治疗的生物标志物。
Malignant pleural mesothelioma (MPM) is an aggressive neoplasm with a poor prognosis. MPM grows from the mesothelial cells lining the surface of the lung and chest wall called Pleura. Exposure to asbestos is mainly linked to the development of MPM. Approximately 80% of the tumors are pleural in origin, and up to 3000 people are diagnosed with MPM in the United States annually. The incidence of MPM is expected to rise in the coming decades particularly in the developing countries. Although there is an increase in the awareness of danger associated with the use of asbestos, its use is still prevalent in Australia and Asia because of its durability and low cost. This further warns and adds to the mortality and morbidity of patients with MPM globally. The traditional treatment strategies have shown only modest improvement towards the disease. MPM is difficult to treat because of the fact that the time between the exposure to asbestos and the appearance of symptoms is extremely delayed, and also due to tumor involvement with the pleural surface and the adjoining tissues such as the chest wall, pericardium and sub-diaphragmatic organs. Despite advances in the diagnostic and treatment approaches the median survival rate for MPM is between 9 to 17 months. The standard care with double agent has shown modest improvement however, multimodality approach using novel targets may have potential to achieve the improvement in the survival rate. In this review we give an update on the conventional treatment modalities and discuss about various molecular targets including receptor EphA2, a novel target gene which may be considered as a biomarker for the diagnosis and treatment of MPM.
登录
查看更多内容
通过腺病毒介导的干扰素-β基因治疗根除腹膜内和远处肿瘤可归因于全身免疫的诱导。
DOI：
--
发表时间：
2001
期刊：
Cancer research.
影响因子：
--
作者：
Odaka,M;Sterman,DH;Wiewrodt,R;Zhang,Y;Kiefer,M;Amin,KM;Gao,GP;Wilson,JM;Barsoum,J;Kaiser,LR;Albelda,SM
通讯作者：
Albelda,SM
影响因子：
7.3
作者：
Beauchamp, Amanda;Debinski, Waldemar
通讯作者：
Debinski, Waldemar
抑制白细胞介素 8 可减少裸鼠模型中的人类恶性胸膜间皮瘤增殖。
DOI：
--
发表时间：
1999
期刊：
Oncology research.
影响因子：
--
作者：
Galffy,G;Mohammed,KA;Nasreen,N;Ward,MJ;Antony,VB
通讯作者：
Antony,VB
人间皮和间皮瘤在体内和培养物中简单上皮角蛋白和波形蛋白的共表达。
影响因子：
11.2
作者：
LaRocca,PJ;Rheinwald,JG
通讯作者：
Rheinwald,JG
一项多机构研究证实了猿病毒 40 在人类恶性间皮瘤中的存在和表达。
DOI：
--
发表时间：
1998
期刊：
Cancer research.
影响因子：
--
作者：
Testa,JR;Carbone,M;Hirvonen,A;Khalili,K;Krynska,B;Linnainmaa,K;Pooley,FD;Rizzo,P;Rusch,V;Xiao,GH
通讯作者：
Xiao,GH